Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow IVVD
Invivyd, Inc. (IVVD) P/E ratio
Invivyd, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| CGEN Compugen Ltd. compare | 5.5× |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)